SuperworthPrecision Biosciences EPS DTIL
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- −$2.79
- Latest quarter, Q2 FY26
- −$1.26
- Fiscal year 2025
- −$5.12
- −369% on the year before
Precision Biosciences' earnings per share was −$2.79 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.26.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$5.12 | −369% |
| FY2024 | $1.90 | n/a |
| FY2023 | −$16.04 | n/a |
| FY2022 | −$42.00 | n/a |
| FY2021 | −$15.90 | n/a |
| FY2020 | −$63.00 | n/a |
| FY2019 | −$96.00 | n/a |
| FY2018 | −$87.30 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.26 | n/a | −$2.79 | |
| Q1 FY26 | −$0.75 | n/a | −$3.66 | |
| Q4 FY25 | $1.06 | n/a | −$5.12 | |
| Q3 FY25 | −$1.84 | n/a | −$8.40 | |
| Q2 FY25 | −$2.13 | −146% | −$8.81 | |
| Q1 FY25 | −$2.21 | −230% | −$2.01 | |
| Q4 FY24 | −$2.22 | n/a | $1.90 | |
| Q3 FY24 | −$2.25 | n/a | $0.06 | |
| Q2 FY24 | $4.67 | n/a | $0.21 | |
| Q1 FY24 | $1.70 | n/a | −$7.59 | |
| Q4 FY23 | −$4.06 | n/a | −$16.04 | |
| Q3 FY23 | −$2.10 | n/a | −$19.78 |
Against its peers
Companies in Healthcare nearest Precision Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| DTILPrecision Biosciences | −$2.79 | |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ELMDElectromed | $1.31 | +56% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| INFUInfuSystem | $0.41 | +78% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| ICCCImmucell | $0.08 | −58% a year |
| VMDViemed Healthcare | $0.36 | +6% a year |
| EMBCEmbecta | $1.47 | +3% a year |
| Peer median | $1.16 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Precision Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.